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Structures of SpCas9 (PDB ID 4UN3 and 4OO8) were analyzed using Pymol (Schrödinger). 
DNA was hand modeled into the non-complementary strand groove (nt-groove) with the 
phosphate backbone making hydrogen bond distance contacts with specificity conferring 
mutations when possible. Electrostatics were calculated using the APBS plugin as part of Pymol. 





Mutants were cloned using the Golden Gate strategy (2). Briefly, wild-type SpCas9 (pX330) or 
wild-type SaCas9 (pX601) were used as template to amplify two PCR fragments, using primers 
that incorporated BsaI (pX330) or BbsI (pX601) restriction sites. BsaI or BbsI digestion results 
in distinct 5’ overhangs which are either compatible to the AgeI or EcoRI overhangs of the 
recipient vector or will reconstitute the desired point mutation at the junction of the two Cas9 
DNA pieces. 
 
Cell culture and transfections 
 
Human embryonic kidney (HEK) cell lines 293T and 293FT (Fisher Scientific) were maintained 
in Dulbecco’s modified Eagle’s medium DMEM (Life technologies) supplemented with 10% 
fetal bovine serum (Gibco) at 37°C with 5% CO2. Cells were plated one day prior to transfection 
in 24- or 96-well plates (Corning) at a density of approximately 120,000 cells per 24-well or 
30,000 cells per 96-well. Transfections were performed with Lipofectamine 2000 (Life 
Technologies) according to the manufacturer’s recommended protocol. Unless otherwise 
specified, cells were transfected with a total of 400ng of Cas9 plasmid with 100-200ng sgRNA 
plasmid per 24-well, or 100ng Cas9 with 25-50ng sgRNA plasmid per 96-well. For each 
transfection, an equal amount of plasmid was delivered to all samples. For cytotoxicity 
experiments, HEK293T cells were transfected with WT or eSpCas9(1.1) and incubated for 72 
hours before measuring cell survival using the CellTiter-Glo (Promega) viability assay, which 
fluoresces in response ATP production by live cells.  
 
Indel analysis by next-generation sequencing (NGS) 
 
Cells were harvested approximately 3 days post transfection. Genomic DNA was extracted using 
a QuickExtract DNA extraction kit (Epicentre) by resuspending pelleted cells in QuickExtract 
(80µL per 24-well, or 20µL per 96-well), followed by incubation at 65°C for 15min, 68°C for 
15min and 98°C for 10-15min. PCR fragments for targeted deep sequencing were generated in 
two step PCR reactions as previously described (3). Briefly, primers with PCR handles for 
second round amplification were used to amplify genomic regions of interest (table.S2), followed 
by a fusion PCR method to attach Illumina P5 adapters as well as unique sample-specific 




Cells were harvested at approximately 24 hr post-transfection, and BLESS was carried out as 
described previously (4, 5). Briefly, a total of 10 million cells were fixed for nuclei isolation and 
permeabilization and then treated with Proteinase K for 4 min at 37 °C before inactivation with 
PMSF. Deproteinated nuclei DSBs were labeled with 200 mM of annealed proximal linkers 
overnight. After Proteinase K digestion of labeled nuclei, chromatin was mechanically sheared 
with a 26G needle before sonication (BioRuptor, 20 min on high, 50% duty cycle). A total of 20 
µg of sheared chromatin was captured on streptavidin beads, washed, and ligated to 200 mM of 
distal linker. Linker hairpins were then cleaved off with I-SceI digestion for 4 h at 37 °C, and 
products were PCR-enriched for 18 cycles before proceeding to library preparation with a 
TruSeq Nano LT Kit (Illumina). For the negative control, cells were mock transfected with 
Lipofectamine 2000 and pUC19 DNA and were parallel processed through the assay.  
 
The calculation of the DSB score to separate the background DSBs from the bona fide Cas9-
induced ones was done as previously described (Ran et al, Nature 2015), and sorting the loci on 
the DSB score revealed the top off-target sites as had been previously identified for these sgRNA 
targets. In order to provide additional detection capability beyond these top off-targets, we found 
from the previous Cas9-BLESS data that a homology-search algorithm could help further 
identify true Cas9-induced DSBs. The homology-search algorithm searched for the best matched 
guide sequence within a region of the genome 50nt on either side of the median of a DSB cluster 
identified in BLESS for all NGG and NAG PAM sequences. A score based on the homology was 
calculated with the following weights: a match between the sgRNA and the genomic sequence 
scores +3, a mismatch is -1, while an insertion or deletion between the sgRNA and genomic 
sequence costs -5. Thereby, an on-target sequence with the full 20bp guide + PAM would score 
69. The final homology score for a DSB cluster was identified as the maximum of the scores 
from all possible sequences. Using these weights, we empirically found that bona fide off-targets 
(for which indels were identified on targeted deep sequencing) and background DSBs were 
separated fully when a threshold of >50 was used for the homology score. Using this homology 













Fig. S1. Schematic sgRNA guided targeting and DNA unwinding.  
 
Cas9 cleaves target DNA in a series of coordinated steps. First, the PAM-interacting domain 
recognizes an NGG sequence 5’ of the target DNA. After PAM binding, the first 10-12 
nucleotides of the target sequence (seed sequence) are sampled for sgRNA:DNA 
complementarity, a process dependent on DNA duplex separation. If the seed sequence 
nucleotides complement the sgRNA, the remainder of DNA is unwound and the full length of 
sgRNA hybridizes with the target DNA strand. We hypothesized the nt-groove between the 
RuvC (teal) and HNH (magenta) domains stabilizes the non-targeted DNA strand (ntDNA) and 
facilitates unwinding through non-specific interactions with negative charges of the DNA 
phosphate backbone. In this model, RNA:target-strand DNA (tDNA) and Cas9:ntDNA 
interactions drive DNA unwinding (top arrow) in competition against tDNA:ntDNA 
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Fig S2. Electrostatics of SpCas9 reveal non-target strand groove. 
 
(A) Crystal structure (4UN3) of SpCas9 paired with sgRNA and target DNA colored by 
electrostatic potential to highlight positively charged regions. Scale is from -10 to 1 keV. (B) 
Identical to panel (A) with HNH domain removed to reveal the sgRNA:DNA heteroduplex. (C) 
Crystal structure (in the same orientation as (A)) colored by domain: HNH (magenta), RuvC 
















































Fig S3. Off-target analysis of generated mutants. 
 
Thirty-one SpCas9 single amino acid mutants were generated and tested for specificity at (A) an 
EMX1 target site and (B) two VEGFA target sites. Mutants combining the top residues that 








































































































































































































































































































































































































































































































































Fig. S4. Annotated SpCas9 amino acid sequence. 
 
Mutations of SpCas9 that altered non-targeted strand groove charges were primarily in the RuvC 
and HNH domains (highlighted in yellow). RuvC (cyan), bridge helix (BH, green), REC (grey), 


















Fig. S5. On-target efficiency screen of SpCas9 mutants.  
 
Screen of top single amino acid mutants and combination mutants at 10 target loci for on-target 
cleavage efficiency. SpCas9 (K855A), eSpCas9(1.0), and eSpCas9(1.1) are highlighted in red.  
 
  











































































































































































Fig. S6. eSpCas9(1.0) and eSpCas9(1.1) outperforms truncated sgRNAs as a strategy for 
improving specificity. 
 
Comparison of the specificity of SpCas9(K855A), eSpCas9(1.0) and eSpCas9(1.1) with 
truncated sgRNAs (tru). Indel frequencies at three loci (EMX1(1), VEGFA(1) and VEGFA(5)) 
were tested at major annotated off-target sites. For both VEGFA target sites, tru-sgRNAs 
increased indel frequency at some off-target sites and generated indels at off-targets not observed 
for WT SpCas9. On target indel percentages are labeled in white. The number of off-target sites 
detectable by targeted deep sequencing for each SpCas9 mutant are listed below the heat map 
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Fig. S7. Diagram of BLESS workflow and reads mapped to an on-target cut site.  
 
(A) Schematic outline of the BLESS workflow. (B) Representative BLESS sequencing for 
forward (red) and reverse (blue) reads mapped to the genome. Reads mapping to Cas9 cut sites 


















Fig. S8. Increasing positive charge in the nt-groove generates can result in increased 
cleavage at off-target sites. 
 
Single amino acid mutants SpCas9(S845K) and SpCas9(L847R) exhibited less specificity than 
WT SpCas9 at the EMX1(1) target site. 
  


















































Fig. S9. Generation of eSaCas9 through mutagenesis of the nt-groove. 
 
An improved specificity variant of S. aureus Cas9 (SaCas9) was generated similarly to eSpCas9. 
(A,B) Single and double amino acid mutants of residues in the groove between the RuvC and 
HNH domains were screened for decreased off-target cutting. (C) Mutants with improved 
specificity were combined to make a variant of SaCas9 that maintained on-target cutting at 
EMX1(7) and had significantly reduced off-target cutting. (D) Crystal structure of SaCas9 








































































































































Fig. S10. Characterization of on-target efficiency for specificity-enhancing mutants 
identified in Anders et al.  
 
Anders et al. previously reported three SpCas9 mutants at the phosphate lock loop (Lys1107, 
Glu1108, Ser1109) in the PI domain which confer specificity to bases 1 and 2 of the sgRNA 
proximal to the PAM (7). These consisted of a single amino acid mutant (K1107A) and two 
mutants in which the Lys-Glu-Ser (KES) sequence was replaced with the dipeptides Lys-Gly 
(KG) and Gly-Gly (GG), respectively. Targeted deep sequencing indicated that these phosphate 





























































Fig. S11. eSpCas9(1.1) is not cytotoxic to human cells.  
 
HEK293T cells were transfected with plasmid encoding WT SpCas9 or eSpCas9(1.1) and 
incubated for 72 hours before measuring cell survival using the CellTiter-Glo assay, which 





















































Fig. S12. Nt-groove mutants are not broadly compatible with truncated guide RNAs. 
 
Truncated guide RNAs (tru) were combined with single amino acid SpCas9 mutants and targeted 
to (A) EMX1(1) or (B) VEGFA(1). While most mutants targeted to EMX1(1) with an 18nt guide 
retained on-target efficiency, those targeted to VEGFA(1) with a 17nt guide were compromised. 




































































Table S1. Golden Gate primers for mutant generation. 
 











































































































Table S2. Guide sequences and primers for targeted deep sequencing 
Name 5' Sequence 3’ 
 
 
PAM Forward Primer Reverse Primer 
VEGFA(1)   G G T G A G T G A G T G T G T G C G T G t G G       CCATCTCATCCCTGCGTGTCTCcGCGTCTTCGAGAGTGAGGAC CCTCTCTATGGGCAGTCGGTGATgGGGGAGAGGGACACACAGAT 
OT1 
 
G C T G A G T G A G T G T A T G C G T G t G G 




T G T G G G T G A G T G T G T G C G T G a G G 
   
CCATCTCATCCCTGCGTGTCTCcTGTCACCACACAGTTACCACCT CCTCTCTATGGGCAGTCGGTGATgGGGAATCTAATGTATGGCATGG 
  
G G T G A G T G A G T G T G T G T G T G a G G 
   
CCATCTCATCCCTGCGTGTCTCcAGGGACCCCTCTGACAGACT CCTCTCTATGGGCAGTCGGTGATgCACACCCACACCCTCATACA 
  
G G T G A G T G A G T G C G T G C G G G t G G 
   
CCATCTCATCCCTGCGTGTCTCcCCTCCCACAGGAATTTGAAG CCTCTCTATGGGCAGTCGGTGATgGCACCCCAACACCTACATCT 
  
A G T G A A T G A G T G T G T G T G T G t G G 
   
CCATCTCATCCCTGCGTGTCTCcATAAGGGGCAAGTTCTGGGCTAT CCTCTCTATGGGCAGTCGGTGATgTGTGACCCAAAAGATTCCCACC 
  
T G T G A G T A A G T G T G T G T G T G t G G 
   
CCATCTCATCCCTGCGTGTCTCcTGATGAAGCTGCCTTTCCTAAGC CCTCTCTATGGGCAGTCGGTGATgCACAGGCACTAACTTCTTCAGCCTA 
  
A C T G T G T G A G T G T G T G C G T G a G G 
   
CCATCTCATCCCTGCGTGTCTCcTCTGCCAGATCCTTAGGCG CCTCTCTATGGGCAGTCGGTGATgCCCCAGCAAAACGCACTG 
  
A G C G A G T G G G T G T G T G C G T G g G G 
   
CCATCTCATCCCTGCGTGTCTCcGACGTCTGGGTCCCGAGC CCTCTCTATGGGCAGTCGGTGATgCCACACACAGCGTCTTCCG 
  
A G T G T G T G A G T G T G T G C G T G t G G 
   
CCATCTCATCCCTGCGTGTCTCcTCCTGTGGAACAACCAGACACC CCTCTCTATGGGCAGTCGGTGATgTCAAAGCTGTATCCCCATTGCCTA 
  
T G T G G G T G A G T G T G T G C G T G a G A 
   
CCATCTCATCCCTGCGTGTCTCcAAGCTGCTGGCTTTCCTAAG CCTCTCTATGGGCAGTCGGTGATgAGCAACGAGACGTTAACCC 
  
A G C G A G T G A G T G T G T G T G T G g G G 
   
CCATCTCATCCCTGCGTGTCTCcAGGACCCAGGTTTGCACT CCTCTCTATGGGCAGTCGGTGATgTTCTGCCACTGGCTTAGCTT 
  
G T A G A G T G A G T G T G T G T G T G t G G 
   
CCATCTCATCCCTGCGTGTCTCcATGATTAGAAACCTGCACTCCCAG CCTCTCTATGGGCAGTCGGTGATgGTAAGTGAATCTCTGTCTGTCTCAT 
  
T G A G T G T G A G T G T G T G C G T G g G G 
   
CCATCTCATCCCTGCGTGTCTCcGTGGGCACCAGGAGCGTAG CCTCTCTATGGGCAGTCGGTGATgCAGGAGGTTAAATCCCTCCTCCA 
  
A G A G A G T G A G T G T G T G C A T G a G G 
   
CCATCTCATCCCTGCGTGTCTCcTTCCCCCATGCTTTTCTTGTGATAG CCTCTCTATGGGCAGTCGGTGATgTCGGGAAACTTACAATCATGGAAGAAT 
  
C G T G A G T G A G T G T G T A C C T G g G G 
   
CCATCTCATCCCTGCGTGTCTCcCTGCCATTGTGAACAGTGCT CCTCTCTATGGGCAGTCGGTGATgAGGCATGAGCCACTGAGACT 
    T G T G A G T G A G T G T G T G T G T G t G A       CCATCTCATCCCTGCGTGTCTCcTATTTTCCCCACCTGGGAGT CCTCTCTATGGGCAGTCGGTGATgAACACAGTCCCATCCTTGAAGT 
VEGFA(5) 
 
G G G T G G G G G G A G T T T G C T C C t G G 




G G G A G G G T G G A G T T T G C T C C t G G 
   
CCATCTCATCCCTGCGTGTCTCcCCTGCAGGTGTCTCCTTTTC CCTCTCTATGGGCAGTCGGTGATgGCCACAGTCGTGTCATCTTG 
  
C G G G G G A G G G A G T T T G C T C C t G G 
   
CCATCTCATCCCTGCGTGTCTCcACTTCTTGGGCAGTGATGGA CCTCTCTATGGGCAGTCGGTGATgTACAAGGTGAGCCTGGGTCT 
  
T A G T G G A G G G A G C T T G C T C C t G G 
   
CCATCTCATCCCTGCGTGTCTCcTGCAAAGCTAAGCAGAGATGC CCTCTCTATGGGCAGTCGGTGATgGAAAGAAAGCCCCACCCTCG 
  
G C G T G G G G G G T G T T T G C T C C c G G 
   
CCATCTCATCCCTGCGTGTCTCcGCAGAGATGCCTATGCCTACAT CCTCTCTATGGGCAGTCGGTGATgCACCCTCGCTCTTTTAGTCTC 
  
T T G G G G G G G C A G T T T G C T C C t G G 
   
CCATCTCATCCCTGCGTGTCTCcACATGCGATTCTGCAGGGAA CCTCTCTATGGGCAGTCGGTGATgTCAGAGGGTGCTGTCTGTCT 
EMX1(1)   G A G T C C G A G C A G A A G A A G A A g G G       CCATCTCATCCCTGCGTGTCTCcCAAAGTACAAACGGCAGAAGC CCTCTCTATGGGCAGTCGGTGATgGTTGCCCACCCTAGTCATTG 
OT1 
 
G A G T T A G A G C A G A A G A A G A A a G G 




G A G T C T A A G C A G A A G A A G A A g A G 




G A G T C C T A G C A G G A G A A G A A g A G 




A A G T C T G A G C A C A A G A A G A A t G G 




G A G G C C G A G C A G A A G A A A G A c G G 
   
CCATCTCATCCCTGCGTGTCTCcTGGGAGAGAGACCCCTTCTT CCTCTCTATGGGCAGTCGGTGATgTCCTGCTCTCACTTAGACTTTCTC 
    A C G T C T G A G C A G A A G A A G A A t G G       CCATCTCATCCCTGCGTGTCTCcGGCCCTTCCTCTGTACTCTATAC CCTCTCTATGGGCAGTCGGTGATgTGCCAGTGCCTCAAGAATGTC 
EMX1(2) 
 
G T C A C C T C C A A T G A C T A G G G t G G 




G G G C A A C C A C A A A C C C A C G A g G G 




G C T T G T C C C T C T G T C A A T G G c G G 




G C G C C A C C G G T T G A T G T G A T g G G 




G A C A T C G A T G T C C T C C C C A T t G G 
   
CCATCTCATCCCTGCGTGTCTCcCAAAGTACAAACGGCAGAAGC CCTCTCTATGGGCAGTCGGTGATgGTTGCCCACCCTAGTCATTG 
EMX1(7)   G C C T C C C C A A A G C C T G G C C A g G G       CCATCTCATCCCTGCGTGTCTCcAACCCACGAGGGCAGAGT CCTCTCTATGGGCAGTCGGTGATgGAGGAGAAGGCCAAGTGGTC 
EMX1(8) 
 
G C C C C G G G C T T C A A G C C C T G t G G 




G G C A G A G T G C T G C T T G C T G C t G G 




G C T A A A G A G G G A A T G G G C T T t G G 




G T T T G G G A G G T C A G A A A T A G g G G 




G T T G G A G C G G G G A G A A G G C C a G G 




G T A G A G T G A G T G T G T G T G T G t G G 




G A A G A A T G G A C A G A A C T C T G a G G 




G A T T C C T G G T G C C A G A A A C A g G G 




G T G G G T G A G T G A G T G C G T G C g G G 




G A G G C T G G G G T G G A G G T G T T g G G 




G G T G A G T G A G T G T G T G T G T G a G G 




G T G T G T G T G T G A G G G T G T A A g G G 




G G G C A G T T T G C T C C T G G C A C a G G 




G G A G A G A G G C T C C C A T C A C G g G G 
   
CCATCTCATCCCTGCGTGTCTCcACTTCTTGGGCAGTGATGGA CCTCTCTATGGGCAGTCGGTGATgTACAAGGTGAGCCTGGGTCT 
ADAMTSL1(1)   G A G A A G A G A A G T G G G G T G G G g G G       CCATCTCATCCCTGCGTGTCTCcAGGACCCAGGTTTGCACT CCTCTCTATGGGCAGTCGGTGATgTTCTGCCACTGGCTTAGCTT 
EMX1(7) (SaCas9) G G C C T C C C C A A A G C C T G G C C A g g G A G t CCATCTCATCCCTGCGTGTCTCcAACCCACGAGGGCAGAGT CCTCTCTATGGGCAGTCGGTGATgGAGGAGAAGGCCAAGTGGTC 
OT1 (SaCas9) G A C C T C C C C A T A G C C T G G C C A g g G A G g CCATCTCATCCCTGCGTGTCTCcGAAGCTTTGAGGGGAATGTG CCTCTCTATGGGCAGTCGGTGATgGTTGTTGCGATTGGTGGATT 
OT2 (SaCas9) G G C C T G C C C A A G G C C T G A C C A a g G G A a CCATCTCATCCCTGCGTGTCTCcGATGCTGCCCTTCTGACCTC CCTCTCTATGGGCAGTCGGTGATgCTGGAAGAAGCTGGGGAAGA 
OT3 (SaCas9) G G C C T - C C C A A A G C C A G G C C A g g G G G a CCATCTCATCCCTGCGTGTCTCcGGCCCTTGCTCTTCAGATTT CCTCTCTATGGGCAGTCGGTGATgATTAGCATGGGGACGCTTTT 
Table S3. BLESS DSB, similarity scores and genomic addresses 
 
 
Target chr pos sequence of homology DSB 
Similarity 
Score 
Indel % (rep 
1) 
Indel % (rep 
2) 
WT SpCas9 VEGFA(1) 
6 43737469 GGTGAGTGAGTGTGTGCGTG tGG 4.98 69 50.92 52.07 
22 37662823 GCTGAGTGAGTGTATGCGTG tGG 1.69 61 35.97 35.46 
5 115434674 TGTGGGTGAGTGTGTGCGTG aGG 1.64 61 44.20 40.93 
5 89440968 AGAGAGTGAGTGTGTGCATG aGG 1.51 58 29.44 34.31 
14 65569158 AGTGAGTGAGTGTGTGTGTG gGG 0.96 62 no data no data 
14 106029030 GGTGAGTGAGTGTGTGTGTG aGG 0.55 65 30.59 28.61 
11 68851137 GGTGAGTGAGTGCGTGCGGG tGG 0.35 61 24.68 25.33 
20 20178283 AGTGTGTGAGTGTGTGCGTG tGG 0.33 62 20.58 18.90 
14 62078772 TGTGAGTAAGTGTGTGTGTG tGG 0.28 58 15.04 12.06 
2 177463424 GGTGAGTGTGTGTGTGCATG tGG 0.26 61 no data no data 
10 98760587 GTTGAGTGAATGTGTGCGTG aGG 0.22 61 no data no data 
19 6109031 GTGAGTGAGTGTGTGTGTGT gAG 0.20 56 no data no data 
14 74353495 AGCGAGTGGGTGTGTGCGTG gGG 0.17 57 4.85 4.45 
 
 




6 43737469 GGTGAGTGAGTGTGTGCGTG tGG 5.10 69 59.73 59.31 
22 37662823 GcTGAGTGAGTGTaTGCGTG tGG 0.68 61 14.73 10.99 
5 115434674 TGTGGGTGAGTGTGTGCGTG aGG 0.51 61 6.33 4.07 
5 89440968 AGAGAGTGAGTGTGTGCATG aGG 0 58 3.05 3.10 
14 65569158 AGTGAGTGAGTGTGTGTGTG gGG 0.81 62 no data no data 
14 106029030 GGTGAGTGAGTGTGTGtGTG aGG 0.99 65 25.52 22.61 
11 68851137 GGTGAGTGAGTGCGTGCGGG tGG 0.00 61 2.47 1.98 
20 20178283 AGTGTGTGAGTGTGTGCGTG tGG 0.00 62 0.20 0.31 
14 62078772 TGTGAGTAAGTGTGTGTGTG tGG 0.00 58 0.09 0.05 
2 177463424 GGTGAGTGTGTGTGTGCATG tGG 0 61 no data no data 
10 98760587 GTTGAGTGAATGTGTGCGTG aGG 0 61 no data no data 
19 6109031 GTGAGTGAGTGTGTGTGTGT gAG 0 56 no data no data 
14 74353495 AGCGAGTGGGTGTGTGCGTG gGG 0.00 57 0.13 0.03 
  




6 43737469 GGTGAGTGAGTGTGTGCGTG tGG 5.88 69 58.18 59.37 
22 37662823 GCTGAGTGAGTGTATGCGTG tGG 0.00 61 0.00 0.13 
5 115434674 TGTGGGTGAGTGTGTGCGTG aGG 0.00 61 0.05 0.01 
5 89440968 AGAGAGTGAGTGTGTGCATG aGG 0 58 0.06 0.05 
14 65569158 AGTGAGTGAGTGTGTGTGTG gGG 0.91 62 no data no data 
14 106029030 GGTGAGTGAGTGTGTGtGTG aGG 1.69 65 27.00 25.11 
11 68851137 GGTGAGTGAGTGCGTGCGGG tGG 0.00 61 0.28 0.41 
20 20178283 AGTGTGTGAGTGTGTGCGTG tGG 0.00 62 0.10 0.09 
14 62078772 TGTGAGTAAGTGTGTGTGTG tGG 0.00 58 0.00 0.00 
2 177463424 GGTGAGTGTGTGTGTGCATG tGG 0 61 no data no data 
10 98760587 GTTGAGTGAATGTGTGCGTG aGG 0 61 no data no data 
19 6109031 GTGAGTGAGTGTGTGTGTGT gAG 0 56 no data no data 





     
  
WT SpCas9 EMX1(1) 
2 73160997 GAGTCCGAGCAGAAGAAGAA gGG 6.13 69 63.56 60.46 
5 45359066 GAGTTAGAGCAGAAGAAGAA aGG 1.43 61 52.12 56.83 
15 44109762 GAGTCTAAGCAGAAGAAGAA gAG 0.84 61 30.19 26.75 
5 9227161 AAGTCTGAGCACAAGAAGAA tGG 0.20 57 4.24 4.66 
8 128801257 GAGTCCTAGCAGGAGAAGAA gAG 0.29 61 4.50 5.21 
  




2 73160997 GAGTCCGAGCAGAAGAAGAA gGG 12.85 69 59.30 56.47 
5 45359066 GAGTTAGAGCAGAAGAAGAA aGG 0.00 61 0.99 1.31 
15 44109762 GAGTCTAAGCAGAAGAAGAA gAG 0.00 61 0.68 1.23 
5 9227161 AAGTCTGAGCACAAGAAGAA tGG 0.00 57 0.00 0.11 
8 128801257 GAGTCCTAGCAGGAGAAGAA gAG 0.00 61 0.20 0.35 
  




2 73160997 GAGTCCGAGCAGAAGAAGAA gGG 13.77 69 52.47 49.36 
5 45359066 GAGTTAGAGCAGAAGAAGAA aGG 0.00 61 0.02 0.03 
15 44109762 GAGTCTAAGCAGAAGAAGAA gAG 0.00 61 0.14 0.00 
5 9227161 AAGTCTGAGCACAAGAAGAA tGG 0.00 57 0.00 0.24 
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